首页> 外文期刊>Cancers >Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects
【24h】

Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects

机译:编码抗小鼠内皮糖蛋白(CD105)shRNA的质粒DNA电转移至B16黑色素瘤肿瘤,具有低和高转移潜力,可产生明显的抗肿瘤作用

获取原文
           

摘要

Endoglin overexpression is associated with highly proliferative tumor endothelium and also with some tumors, including melanoma. Its targeting has anti-tumor effectiveness, which can also be obtained by RNA interference. The aim of our study was to explore the anti-tumor effectiveness of endoglin silencing by electrotransfer of plasmid DNA encoding short hairpin RNA against endoglin in two murine B16 melanoma variants with different metastatic potential on cells, spheroids and subcutaneous tumors in mice. The results demonstrate that endoglin silencing with gene electrotransfer reduces the proliferation, survival and migration of melanoma cells and also has anti-tumor effectiveness, as the therapy resulted in a high percentage of tumor cures (23% and 58% on B16F1 and B16F10 tumors, respectively). The effectiveness of the therapy correlated with endoglin expression in melanoma cells; in vitro the effects were more pronounced in B16F1 cells, which express more endoglin than B16F10. However, the opposite was observed in vivo in tumors, where there was a higher expression of endoglin and better anti-tumor effectiveness in the B16F10 tumor. In conclusion, targeting endoglin for the treatment of melanoma seems to be a concept worthy of further exploration due to the increased therapeutic effect of the therapy based on simultaneous vascular targeting and its direct effect on tumor cells.
机译:内皮糖蛋白的过表达与高度增殖的肿瘤内皮有关,也与包括黑素瘤在内的某些肿瘤有关。其靶向具有抗肿瘤效力,这也可以通过RNA干扰获得。我们的研究目的是通过电转移编码短发夹RNA的质粒DNA对抗内皮糖蛋白,对两种小鼠B16黑色素瘤变种在小鼠的细胞,类球体和皮下肿瘤上具有不同转移潜能的内皮糖蛋白的抗肿瘤作用进行研究。结果表明,通过基因电转移使内皮糖蛋白沉默可降低黑色素瘤细胞的增殖,存活和迁移,并且还具有抗肿瘤效果,因为该疗法可导致较高的肿瘤治愈率(B16F1和B16F10肿瘤分别为23%和58%,分别)。该疗法的有效性与黑色素瘤细胞中内皮糖蛋白的表达有关;在体外,这种作用在B16F1细胞中更为明显,B16F1细胞比B16F10表达更多的内皮糖蛋白。然而,在体内观察到相反的情况,其中在B16F10肿瘤中内皮糖蛋白的表达更高并且抗肿瘤效果更好。综上所述,靶向内皮糖蛋白治疗黑色素瘤似乎是值得进一步探索的概念,因为基于同时血管靶向的治疗方法的治疗作用增强及其对肿瘤细胞的直接作用。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号